Importantly, the combination of 17-AAG and TRAIL resulted in greater tumor growth inhibition compared to single agents in both RKO and SW620 colorectal tumor xenografts (Fig. 6A). The gene discussed is TNFSF10; the disease is colorectal neoplasm.